Angina, exercise and food.

A. Harcombe,L. Shapiro

DOI: https://doi.org/10.1093/OXFORDJOURNALS.EURHEARTJ.A014863

IF: 39.3

1996-03-01

European Heart Journal

Abstract:

What problem does this paper attempt to address?

Brugada Syndrome: Clinical, Genetic, Molecular, Cellular, and Ionic Aspects

Charles Antzelevitch,Bence Patocskai

DOI: https://doi.org/10.1016/j.cpcardiol.2015.06.002

Abstract:Brugada syndrome (BrS) is an inherited cardiac arrhythmia syndrome first described as a new clinical entity in 1992. Electrocardiographically characterized by distinct coved type ST segment elevation in the right-precordial leads, the syndrome is associated with a high risk for sudden cardiac death in young adults, and less frequently in infants and children. The electrocardiographic manifestations of BrS are often concealed and may be unmasked or aggravated by sodium channel blockers, a febrile state, vagotonic agents, as well as by tricyclic and tetracyclic antidepressants. An implantable cardioverter defibrillator is the most widely accepted approach to therapy. Pharmacologic therapy is designed to produce an inward shift in the balance of currents active during the early phases of the right ventricular action potential (AP) and can be used to abort electrical storms or as an adjunct or alternative to device therapy when use of an implantable cardioverter defibrillator is not possible. Isoproterenol, cilostazol, and milrinone boost calcium channel current and drugs like quinidine, bepridil, and the Chinese herb extract Wenxin Keli inhibit the transient outward current, acting to diminish the AP notch and thus to suppress the substrate and trigger for ventricular tachycardia or fibrillation. Radiofrequency ablation of the right ventricular outflow tract epicardium of patients with BrS has recently been shown to reduce arrhythmia vulnerability and the electrocardiographic manifestation of the disease, presumably by destroying the cells with more prominent AP notch. This review provides an overview of the clinical, genetic, molecular, and cellular aspects of BrS as well as the approach to therapy.
Patient-Specific and Genome-Edited Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Brugada Syndrome

Ping Liang,Karim Sallam,Haodi Wu,Yingxin Li,Ilanit Itzhaki,Priyanka Garg,Ying Zhang,Vittavat Vermglinchan,Feng Lan,Mingxia Gu,Tingyu Gong,Yan Zhuge,Chunjiang He,Antje D. Ebert,Veronica Sanchez-Freire,Jared Churko,Shijun Hu,Arun Sharma,Chi Keung Lam,Melvin M. Scheinman,Donald M. Bers,Joseph C. Wu

DOI: https://doi.org/10.1016/j.jacc.2016.07.779

IF: 24

2016-01-01

Journal of the American College of Cardiology

Abstract:BACKGROUND Brugada syndrome (BrS), a disorder associated with characteristic electrocardiogram precordial ST-segment elevation, predisposes afflicted patients to ventricular fibrillation and sudden cardiac death. Despite marked achievements in outlining the organ level pathophysiology of the disorder, the understanding of human cellular phenotype has lagged due to a lack of adequate human cellular models of the disorder.OBJECTIVES The objective of this study was to examine single cell mechanism of Brugada syndrome using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs).METHODS This study recruited 2 patients with type 1 BrS carrying 2 different sodium voltage-gated channel alpha subunit 5 variants as well as 2 healthy control subjects. We generated iPSCs from their skin fibroblasts by using integration-free Sendai virus. We used directed differentiation to create purified populations of iPSC-CMs.RESULTS BrS iPSC-CMs showed reductions in inward sodium current density and reduced maximal upstroke velocity of action potential compared with healthy control iPSC-CMs. Furthermore, BrS iPSC-CMs demonstrated increased burden of triggered activity, abnormal calcium (Ca2+) transients, and beating interval variation. Correction of the causative variant by genome editing was performed, and resultant iPSC-CMs showed resolution of triggered activity and abnormal Ca2+ transients. Gene expression profiling of iPSC-CMs showed clustering of BrS compared with control subjects. Furthermore, BrS iPSC-CM gene expression correlated with gene expression from BrS human cardiac tissue gene expression.CONCLUSIONS Patient-specific iPSC-CMs were able to recapitulate single-cell phenotype features of BrS, including blunted inward sodium current, increased triggered activity, and abnormal Ca2+ handling. This novel human cellular model creates future opportunities to further elucidate the cellular disease mechanism and identify novel therapeutic targets. (C) 2016 by the American College of Cardiology Foundation.
Patient-specific Ipsc-Derived Cardiomyocytes Reveal Aberrant Activation of Wnt/β-catenin Signaling in SCN5A-related Brugada Syndrome

Dongsheng Cai,Xiaochen Wang,Yaxun Sun,Hangping Fan,Jingjun Zhou,Zongkuai Yang,Hangyuan Qiu,Jue Wang,Jun Su,Tingyu Gong,Chenyang Jiang,Ping Liang

DOI: https://doi.org/10.1186/s13287-023-03477-3

2023-01-01

Stem Cell Research & Therapy

Abstract:Mutations in the cardiac sodium channel gene SCN5A cause Brugada syndrome (BrS), an arrhythmic disorder that is a leading cause of sudden death and lacks effective treatment. An association between SCN5A and Wnt/β-catenin signaling has been recently established. However, the role of Wnt/β-catenin signaling in BrS and underlying mechanisms remains unknown. Three healthy control subjects and one BrS patient carrying a novel frameshift mutation (T1788fs) in the SCN5A gene were recruited in this study. Control and BrS patient-specific induced pluripotent stem cells (iPSCs) were generated from skin fibroblasts using nonintegrated Sendai virus. All iPSCs were differentiated into cardiomyocytes using monolayer-based differentiation protocol. Action potentials and sodium currents were recorded from control and BrS iPSC-derived cardiomyocytes (iPSC-CMs) by single-cell patch clamp. BrS iPSC-CMs exhibited increased burden of arrhythmias and abnormal action potential profile featured by slower depolarization, decreased action potential amplitude, and increased beating interval variation. Moreover, BrS iPSC-CMs showed cardiac sodium channel (Nav1.5) loss-of-function as compared to control iPSC-CMs. Interestingly, the electrophysiological abnormalities and Nav1.5 loss-of-function observed in BrS iPSC-CMs were accompanied by aberrant activation of Wnt/β-catenin signaling. Notably, inhibition of Wnt/β-catenin significantly rescued Nav1.5 defects and arrhythmic phenotype in BrS iPSC-CMs. Mechanistically, SCN5A-encoded Nav1.5 interacts with β-catenin, and reduced expression of Nav1.5 leads to re-localization of β-catenin in BrS iPSC-CMs, which aberrantly activates Wnt/β-catenin signaling to suppress SCN5A transcription. Our findings suggest that aberrant activation of Wnt/β-catenin signaling contributes to the pathogenesis of SCN5A-related BrS and point to Wnt/β-catenin as a potential therapeutic target.
Cellular Modeling and Simulation of Brugada Syndrome

L Xia,Y Zhang,XH Lu

DOI: https://doi.org/10.1109/cic.2005.1588279

2005-01-01

Abstract:A mathematical model of the action potential (AP) of human ventricular cell is constructed and used in simulation studies of Brugada syndrome. The model is based on Luo-Rudy model, and refined by recent experimental data on major ionic currents, and the formulations of ten Tusscher et al are also introduced into our model. The results show that the endocardial and midmyocardial cells AP have little changes in Brugada syndrome compared with that of normal heart, but the epicardial cell AP changes obviously. We also investigate the temperature dependent and heart rate dependent Brugada syndrome. The results show that when the body temperature increases to 39.5degC or the cardiac length is larger than 1000 ms, the Brugada syndrome epicardial cell APs may appear suddenly change, which is very likely to induce sudden death. The result may explain why some Brugada syndrome patients easily to die suddenly during a febrile state or during the night when they are sleeping. These results are in good accordance with the experiment findings reported in the literatures
Activation of ENaC by AVP contributes to the urinary concentrating mechanism and dilution of plasma.

Elena V. Mironova,Yu Chen,Alan C. Pao,Karl P Roos,D. Kohan,V. Bugaj,J. Stockand

DOI: https://doi.org/10.1152/ajprenal.00246.2014

2015-02-01

Abstract:Arginine vasopressin (AVP) activates the epithelial Na(+) channel (ENaC). The physiological significance of this activation is unknown. The present study tested if activation of ENaC contributes to AVP-sensitive urinary concentration. Consumption of a 3% NaCl solution induced hypernatremia and plasma hypertonicity in mice. Plasma AVP concentration and urine osmolality increased in hypernatremic mice in an attempt to compensate for increases in plasma tonicity. ENaC activity was elevated in mice that consumed 3% NaCl solution compared with mice that consumed a diet enriched in Na(+) with ad libitum tap water; the latter diet does not cause hypernatremia. To determine whether the increase in ENaC activity in mice that consumed 3% NaCl solution served to compensate for hypernatremia, mice were treated with the ENaC inhibitor benzamil. Coadministration of benzamil with 3% NaCl solution decreased urinary osmolality and increased urine flow so that urinary Na(+) excretion increased with no effect on urinary Na(+) concentration. This decrease in urinary concentration further increased plasma Na(+) concentration, osmolality, and AVP concentration in these already hypernatremic mice. Benzamil similarly compromised urinary concentration in water-deprived mice and in mice treated with desmopressin. These results demonstrate that stimulation of ENaC by AVP plays a critical role in water homeostasis by facilitating urinary concentration, which can compensate for hypernatremia or exacerbate hyponatremia. The present findings are consistent with ENaC in addition to serving as a final effector of the renin-angiotensin-aldosterone system and blood pressure homeostasis, also playing a key role in water homeostasis by regulating urine concentration and dilution of plasma.
Ablation for the treatment of Brugada syndrome: current status and future prospects

Alessandro Rizzo,Carlo de Asmundis,Pedro Brugada,Mark La Meir,Gian-Battista Chierchia

DOI: https://doi.org/10.1080/17434440.2020.1719831

IF: 3.439

2020-01-27

Expert Review of Medical Devices

Abstract:Introduction: Brugada syndrome (BrS) is an inherited disease characterized by an increased risk of sudden cardiac death (SCD). Therapeutic options in symptomatic patients are limited to implantable cardioverter defibrillator (ICD) and quinidine, but catheter ablation of the right ventricular outflow tract (RVOT) offers a potential cure. Different ablation strategies have been used to treat patients with symptomatic Brugada syndrome. Epicardial radiofrequency substrate ablation of the RVOT/right ventricle (RV) has emerged as a promising tool for the management of the disease.Areas covered: The historical management of BrS, endocardial and epicardial ablation techniques, the use of sodium channel blockers (SCB) and complications are summarized here.Expert opinion: Ventricular fibrillation (VF)-triggering premature ventricular contractions (PVCs) in patients with BrS are unpredictable, spontaneous ones are rarely present to be mapped, making this approach impractical. Furthermore, endocardial mapping for BrS substrates does not seem effective due to the epicardial pathological substrate localization. The size variation of the BrS substrate areas during SCB infusion suggests a dynamic process as arrhythmogenic basis and SCB infusion should guide BrS epicardial ablation of all abnormal potentials areas. If BrS epicardial ablation can truly provide long-term prevention of ventricular arrhythmias it may potentially become an alternative to ICD therapy.

engineering, biomedical
Long-Term Outcomes of Brugada Substrate Ablation: A Report from BRAVO (brugada Ablation of VF Substrate Ongoing Multicenter Registry).

Koonlawee Nademanee,Fa-Po Chung,Frederic Sacher,Akihiko Nogami,Hiroshi Nakagawa,Chenyang Jiang,Meleze Hocini,Elijah Behr,Gumpanart Veerakul,Jaap Jan Smit,Arthur A. M. Wilde,Shih-Ann Chen,Kohei Yamashiro,Yuichiro Sakamoto,Itsuro Morishima,Mithilesh K. Das,Apichai Khongphatthanayothin,Saran Vardhanabhuti,Michel Haissaguerre

DOI: https://doi.org/10.1161/circulationaha.122.063367

IF: 37.8

2023-01-01

Circulation

Abstract:BACKGROUND:Treatment options for high-risk Brugada syndrome (BrS) with recurrent ventricular fibrillation (VF) are limited. Catheter ablation is increasingly performed but a large study with long-term outcome data is lacking. We report the results of the multicenter, international BRAVO (Brugada Ablation of VF Substrate Ongoing Registry) for treatment of high-risk symptomatic BrS.METHODS:We enrolled 159 patients (median age 42 years; 156 male) with BrS and spontaneous VF in BRAVO; 43 (27%) of them had BrS and early repolarization pattern. All but 5 had an implantable cardioverter-defibrillator for cardiac arrest (n=125) or syncope (n=34). A total of 140 (88%) had experienced numerous implantable cardioverter-defibrillator shocks for spontaneous VF before ablation. All patients underwent a percutaneous epicardial substrate ablation with electroanatomical mapping except for 8 who underwent open-thoracotomy ablation.RESULTS:In all patients, VF/BrS substrates were recorded in the epicardial surface of the right ventricular outflow tract; 45 (29%) patients also had an arrhythmic substrate in the inferior right ventricular epicardium and 3 in the posterior left ventricular epicardium. After a single ablation procedure, 128 of 159 (81%) patients remained free of VF recurrence; this number increased to 153 (96%) after a repeated procedure (mean 1.2±0.5 procedures; median=1), with a mean follow-up period of 48±29 months from the last ablation. VF burden and frequency of shocks decreased significantly from 1.1±2.1 per month before ablation to 0.003±0.14 per month after the last ablation (P<0.0001). The Kaplan-Meier VF-free survival beyond 5 years after the last ablation was 95%. The only variable associated with a VF-free outcome in multivariable analysis was normalization of the type 1 Brugada ECG, both with and without sodium-channel blockade, after the ablation (hazard ratio, 0.078 [95% CI, 0.008 to 0.753]; P=0.0274). There were no arrhythmic or cardiac deaths. Complications included hemopericardium in 4 (2.5%) patients.CONCLUSIONS:Ablation treatment is safe and highly effective in preventing VF recurrence in high-risk BrS. Prospective studies are needed to determine whether it can be an alternative treatment to implantable cardioverter-defibrillator implantation for selected patients with BrS.REGISTRATION:URL: https://www.CLINICALTRIALS:gov; Unique identifier: NCT04420078.
Novelties in Brugada Syndrome: Complex Genetics, Risk Stratification, and Catheter Ablation

Wiert F Hoeksema,Ahmad S Amin,Connie R Bezzina,Arthur A M Wilde,Pieter G Postema

DOI: https://doi.org/10.1016/j.ccep.2023.05.002

Abstract:Brugada syndrome (BrS) is an inherited arrhythmia syndrome with distinctive electrocardiographic abnormalities in the right precordial leads and predisposes to ventricular arrhythmias and sudden cardiac death in otherwise healthy patients. Its complex genetic architecture and pathophysiological mechanism are not yet completely understood, and risk stratification remains challenging, particularly in patients at intermediate risk of arrhythmic events. Further understanding of its complex genetic architecture may help improving future risk stratification, and advances in management may contribute to alternatives to implantable cardioverter-defibrillators. Here, the authors review the latest insights and developments in BrS.
Genetic and Molecular Mechanisms in Brugada Syndrome

Errol Moras,Kruti Gandhi,Bharat Narasimhan,Ramon Brugada,Josep Brugada,Pedro Brugada,Chayakrit Krittanawong

DOI: https://doi.org/10.3390/cells12131791

IF: 6

2023-07-06

Cells

Abstract:Brugada syndrome is a rare hereditary arrhythmia disorder characterized by a distinctive electrocardiogram pattern and an elevated risk of ventricular arrhythmias and sudden cardiac death in young adults. Despite recent advances, it remains a complex condition, encompassing mechanisms, genetics, diagnosis, arrhythmia risk stratification, and management. The underlying electrophysiological mechanism of Brugada syndrome requires further investigation, with current theories focusing on abnormalities in repolarization, depolarization, and current-load match. The genetic basis of the syndrome is strong, with mutations found in genes encoding subunits of cardiac sodium, potassium, and calcium channels, as well as genes involved in channel trafficking and regulation. While the initial discovery of mutations in the SCN5A gene provided valuable insights, Brugada syndrome is now recognized as a multifactorial disease influenced by several loci and environmental factors, challenging the traditional autosomal dominant inheritance model. This comprehensive review aims to provide a current understanding of Brugada syndrome, focusing on its pathophysiology, genetic mechanisms, and novel models of risk stratification. Advancements in these areas hold the potential to facilitate earlier diagnosis, improve risk assessments, and enable more targeted therapeutic interventions.

cell biology
Brugada syndrome: current clinical aspects and risk stratification

Takanori Ikeda

DOI: https://doi.org/10.1111/j.1542-474x.2002.tb00172.x

Abstract:Brugada syndrome is a primary electrical disease of the heart that causes sudden cardiac death or life-threatening ventricular arrhythmias, especially in younger men. Genetic analysis supports that this syndrome is a cardiac ion channel disease. A typical electrocardiographic finding consists of a right bundle branch block pattern and ST-segment elevation in the right precordial leads. The higher intercostal space V(1) to V(3) lead electrocardiogram could be helpful in detecting Brugada patients. Although two types of the ST-segment elevation are present, the coved type is more relevant to the syndrome than the saddle-back type. These patterns can be present permanently or intermittently. Recent data suggest that the Brugada-type electrocardiogram is more prevalent than the manifest Brugada syndrome. Asymptomatic individuals have a much lower incidence of future cardiac events than the symptomatic patients. Although risk stratification for the Brugada syndrome is still incomplete, the inducibility of sustained ventricular arrhythmias has been proposed as a good outcome predictor in this syndrome. In noninvasive techniques, some clinical evidence supports that late potentials detected by signal-averaged electrocardiography are a useful index for identifying patients at risk. The available data recommend prophylactic implantation of an implantable cardioverter defibrillator to prevent sudden cardiac death. This review summarizes recent information of the syndrome by reviewing most of new clinical reports and speculates on its risk stratification.
Why Is Only Type 1 Electrocardiogram Diagnostic of Brugada Syndrome? Mechanistic Insights From Computer Modeling

Zhaoyang Zhang,Peng-Sheng Chen,James N Weiss,Zhilin Qu

DOI: https://doi.org/10.1161/CIRCEP.121.010365

2022-01-01

Abstract:BACKGROUND: Three types of characteristic ST-segment elevation are associated with Brugada syndrome but only type 1 is diagnostic. Why only type 1 ECG is diagnostic remains unanswered. METHODS: Computer simulations were performed in single cells, 1-dimensional cables, and 2-dimensional tissues to investigate the effects of the peak and late components of the transient outward potassium current (I-to), sodium current, and L-type calcium current (I-ca,I-L) as well as other potassium currents on the genesis of ECG morphologies and phase 2 reentry (P2R). RESULTS: Although a sufficiently large peak I-to was required to result in the type 1 ECG pattern and P2R, increasing the late component of I-to converted type 1 ECG to type 2 ECG and suppressed P2R. Increasing the peak I-to promoted spiral wave breakup, potentiating the transition from tachycardia to fibrillation, but increasing the late I-to prevented spiral wave breakup by flattening the action potential duration restitution and preventing P2R. A sufficiently large I-Ca,I-L conductance was needed for P2R to occur, but once above the critical conductance, blocking I-Ca,I-L promoted P2R. However, selectively blocking the window and late components of 1, 081 suppressed P2R, countering the effect of the late I-to, Blocking either the peak or late components of sodium current promoted P2R, with the late sodium current blockade having the larger effect. As expected, increasing other potassium currents potentiated P2R, with ATP-sensitive potassium current exhibiting a larger effect than rapid and slow component of the delayed rectifier potassium current. CONCLUSIONS: The peak I-to promotes type 1 ECG and P2R, whereas the late I-to converts type 1 ECG to type 2 ECG and suppresses P2R. Blocking the peak I-CaL and either the peak or the late sodium current promotes P2R, whereas blocking the window and late I-CaL suppresses P2R. these results provide important insights into the mechanisms of arrhythmogenesis and potential therapeutic targets for treatment of Brugada syndrome. [GRAPHICS] .
Brugada syndrome: identification of subjects at risk and therapy

Fiorenzo Gaita,Natascia Cerrato,Carla Giustetto,Lucia Garberoglio,Leonardo Calò

DOI: https://doi.org/10.1093/eurheartjsupp/suae021

2024-04-01

European Heart Journal Supplements

Abstract:Abstract Brugada syndrome mainly affects young subjects with structurally normal heart and can cause x syncope or sudden death due to ventricular arrhythmias, even as the first manifestation, in approximately 5–10% of cases. To date, two questions remain open: how to recognize subjects who will experience arrhythmic events and how to treat them. The guidelines suggest treating subjects with a previous history of cardiac arrest or arrhythmogenic syncope, while they are unconclusive about the management of asymptomatic patients, who represent ∼90% of Brugada patients. We recently demonstrated that in asymptomatic patients, the presence of spontaneous Brugada type 1 electrocardiogram (ECG) pattern and inducibility of ventricular arrhythmias at electrophysiological study allows us to identify a group of patients at greater risk who deserve treatment. Regarding treatment, there are three options: implantable cardioverter defibrillator, drugs, and epicardial transcatheter ablation. Recent studies have shown that the latter is effective and free from serious side effects, thus opening a new scenario in the treatment of Brugada patients at risk. Subjects who present drug-induced-only type 1 Brugada ECG pattern, in whom a spontaneous type 1 pattern has been ruled out with repeated ECGs and 12-lead 24-h Holter monitoring, represent a very low-risk group, provided they adhere to behavioural recommendations and undergo regular follow-up.

cardiac & cardiovascular systems
Brugada Syndrome: From Molecular Mechanisms and Genetics to Risk Stratification

Irene Paula Popa,Dragomir N. Șerban,Minela Aida Mărănducă,Ionela Lăcrămioara Șerban,Bogdan Ionel Tamba,Ionuț Tudorancea

DOI: https://doi.org/10.3390/ijms24043328

IF: 5.6

2023-02-07

International Journal of Molecular Sciences

Abstract:Brugada syndrome (BrS) is a rare hereditary arrhythmia disorder, with a distinctive ECG pattern, correlated with an increased risk of ventricular arrhythmias and sudden cardiac death (SCD) in young adults. BrS is a complex entity in terms of mechanisms, genetics, diagnosis, arrhythmia risk stratification, and management. The main electrophysiological mechanism of BrS requires further research, with prevailing theories centered on aberrant repolarization, depolarization, and current-load match. Computational modelling, pre-clinical, and clinical research show that BrS molecular anomalies result in excitation wavelength (k) modifications, which eventually increase the risk of arrhythmia. Although a mutation in the SCN5A (Sodium Voltage-Gated Channel Alpha Subunit 5) gene was first reported almost two decades ago, BrS is still currently regarded as a Mendelian condition inherited in an autosomal dominant manner with incomplete penetrance, despite the recent developments in the field of genetics and the latest hypothesis of additional inheritance pathways proposing a more complex mode of inheritance. In spite of the extensive use of the next-generation sequencing (NGS) technique with high coverage, genetics remains unexplained in a number of clinically confirmed cases. Except for the SCN5A which encodes the cardiac sodium channel NaV1.5, susceptibility genes remain mostly unidentified. The predominance of cardiac transcription factor loci suggests that transcriptional regulation is essential to the Brugada syndrome’s pathogenesis. It appears that BrS is a multifactorial disease, which is influenced by several loci, each of which is affected by the environment. The primary challenge in individuals with a BrS type 1 ECG is to identify those who are at risk for sudden death, researchers propose the use of a multiparametric clinical and instrumental strategy for risk stratification. The aim of this review is to summarize the latest findings addressing the genetic architecture of BrS and to provide novel perspectives into its molecular underpinnings and novel models of risk stratification.

biochemistry & molecular biology,chemistry, multidisciplinary
Efficacy and safety of catheter ablation for Brugada syndrome: an updated systematic review

Yasuhito Kotake,Sumita Barua,Samia Kazi,Sohaib Virk,Ashwin Bhaskaran,Timothy Campbell,Richard G. Bennett,Saurabh Kumar

DOI: https://doi.org/10.1007/s00392-022-02020-3

IF: 6.138

2022-04-22

Clinical Research in Cardiology

Abstract:Abstract Background Patients with Brugada syndrome (BrS) may experience recurrent ventricular arrhythmias (VAs). Catheter ablation is becoming an emerging paradigm for treatment of BrS. Objective To assess the efficacy and safety of catheter ablation in BrS in an updated systematic review. Methods We comprehensively searched the databases of Pubmed/Medline, EMBASE, and Cochrane Central Register of Controlled Trials from inception to 11th of August 2021. Results Fifty-six studies involving 388 patients were included. A substrate-based strategy was used in 338 cases (87%), and a strategy of targeting premature ventricular complex (PVCs)/ventricular tachycardias (VTs) that triggered ventricular fibrillation (VF) in 47 cases (12%), with combined abnormal electrogram and PVC/VT ablation in 3 cases (1%). Sodium channel blocker was frequently used to augment the arrhythmogenic substrate in 309/388 cases (80%), which included a variety of agents, of which ajmaline was most commonly used. After ablation procedure, the pooled incidence of non-inducibility of VA was 87.1% (95% confidence interval [CI], 73.4–94.3; I 2 = 51%), and acute resolution of type I ECG was seen in 74.5% (95% CI [52.3–88.6]; I 2 = 75%). Over a weighted mean follow up of 28 months, 7.6% (95% CI [2.1–24]; I 2 = 67%) had recurrence of type I ECG either spontaneously or with drug challenge and 17.6% (95% CI [10.2–28.6]; I 2 = 60%) had recurrence of VA. Conclusion Catheter ablation appears to be an efficacious strategy for elimination of arrhythmias or substrate associated with BrS. Further study is needed to identify which patients stand to benefit, and optimal provocation protocol for identifying ablation targets. Graphical abstract

cardiac & cardiovascular systems
Brugada Syndrome: Focus for the General Pediatrician

Alessia Speranzon,Daniela Chicco,Paolo Bonazza,Raffaele D’Alfonso,Marco Bobbo,Biancamaria D’Agata Mottolese,Egidio Barbi,Thomas Caiffa

DOI: https://doi.org/10.3390/children11030281

2024-02-25

Children

Abstract:Brugada Syndrome is an “inherited” channelopathy characterized by a predisposition to syncope and sudden death. It typically presents in young adults but is also known to affect the pediatric population, even if the prevalence is low compared to the adult population. The diagnostic ECG pattern shows coved-type ST-segment elevation in the right precordial leads, occurring spontaneously or after provocative drug tests with IV administration of Class I antiarrhythmic drugs. However, the electrocardiographic findings may vary, and transient or concealed forms of the syndrome further complicate diagnosis, necessitating thorough evaluation and close clinical follow-up. The clinical presentation of Brugada Syndrome may range from asymptomatic individuals to patients who have experienced syncope or sudden cardiac arrest. The syndrome remains underdiagnosed due to its elusive symptoms and the absence of abnormal findings between episodes. Additionally, specific triggers such as fever, certain medications and alcohol consumption may unmask the electrocardiographic changes and provoke arrhythmias in susceptible individuals. Given its elusive nature, early diagnosis and risk stratification are crucial in identifying individuals who may benefit from an implantable cardioverter defibrillator, the mainstay of treatment for high-risk patients, or pharmacological interventions.

pediatrics
Characterization of the Epicardial Substrate for Catheter Ablation of Brugada Syndrome.

Pei Zhang,Roderick Tung,Zuwen Zhang,Xia Sheng,Qiang Liu,Ruhong Jiang,Yaxun Sun,Shiquan Chen,Lu Yu,Yang Ye,Guosheng Fu,Kalyanam Shivkumar,Chenyang Jiang

DOI: https://doi.org/10.1016/j.hrthm.2016.07.025

IF: 6.779

2016-01-01

Heart Rhythm

Abstract:BACKGROUND Catheter ablation in the right ventricular outflow tract (RVOT) may modify the electrophysiologic substrate for recurrent ventricular tachycardia/ventricular fibrillation (VT/VF) in patients with Brugada syndrome (BrS).OBJECTIVE The purpose of this study was to investigate the mechanism and arrhythmogenic substrate of VT/VF and to evaluate the long-term outcomes of catheter ablation in patients with BrS.METHODS Eleven consecutive patients with BrS referred to 2 academic medical centers underwent combined epicardial-endocardial electroanatomic mapping. Catheter ablation was performed in regions of localized conduction slowing. Transmural dispersion of late activation was calculated as the difference between the latest activation between epicardium and endocardium, and low voltage areas were analyzed.RESULTS Eleven patients met diagnostic criteria for BrS (spontaneous type 1, n = 9; Na channel provocation = 2). All patients were found to have a localized region in the anterior epicardial RVOT with conduction slowing evidenced by prolonged electrogram duration (78.79 +/- 19.87 ms vs 58.93 +/- 10.11 ms in epicardial right ventricle, and 59.87 +/- 12.61 ms in endocardial RVOT, P <.005, respectively) with variable low voltage (0.97 +/- 0.48 mV; median scar area 19.8 +/- 25.9 cm(2)). Epicardial ablation resulted in normalization of spontaneous type 1 Brugada ECG pattern in all patients, and 73% were free from VT/VF at 25 +/- 11 months.CONCLUSION Prolonged electrograms localized to epicardial RVOT with variable low voltage were identified in all patients with BrS. J-point and ST-segment elevation correlated with greater transmural dispersion of late activation and was independent of total low voltage area. Despite normalization of spontaneous type 1 pattern in all patients after ablation, recurrence was still observed, suggesting the implantable cardioverter-defibrillator as the cornerstone therapy for BrS. (C) 2016 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
Incidence, recurrence and management of electrical storm in Brugada syndrome

Ibrahim El-Battrawy,Gretje Roterberg,Jacqueline Kowitz,Assem Aweimer,Siegfried Lang,Andreas Mügge,Xiaobo Zhou,Ibrahim Akin

DOI: https://doi.org/10.3389/fcvm.2022.981715

IF: 3.6

2022-10-26

Frontiers in Cardiovascular Medicine

Abstract:Background: Brugada syndrome (BrS) is associated with ventricular tachyarrhythmias. However, the presence of electrical strom (ES) and its management still debated. Objectives: We present the outcome and management of 44 BrS patients suffering from ES. Methods: A systematic literature review and pooled analysis Through database review including PubMed, Web of Science, Cochrane Libary and Cinahl studies were analyzed. Evidence from 7 reports of 808 BrS patients was identified. Results: The mean age of patients suffering from ES was 34 ± 9.5 months (94.7% males, 65.8% spontaneous BrS type I). Using electrophysiological study ventricular tachycardia/ventricular fibrillation were inducible in 12/23 (52.2%). Recurrence of ES was documented in 6.1%. Death from ES was 8.2% after a follow-up of 83.5 ± 53.4. In up to 27 ES resolved without treatment. External shock was required in 35.6%, internal ICD shock in 13.3%, Overdrive pacing, left cardiac sympathetic block and atropin in 2.2%. Short-term antiarrhythmic management was as the following: Isopreterenol or Isopreterenol in combination with quinidine 35.5%, orciprenaline in 2.2%, quinidine 2.2%, disopyramide 2.2% or denopamide 2.2%. However, lidocaine, magensium sulfate, mexiletine and propanolol failed to control ES. Conclusion: Although ES is rare in BrS, this entity challenges physicians. Despite its high mortality rate, spontaneous termination is possible. Short-term management using Isoproterenol and/or quinidine might be safe. Prospective studies on management of ES are warranted.

cardiac & cardiovascular systems
Phase 2 Re-Entry Without Ito: Role of Sodium Channel Kinetics in Brugada Syndrome Arrhythmias.

Zhaoyang Zhang,Pedro Brugada,James N. Weiss,Zhilin Qu

DOI: https://doi.org/10.1016/j.jacep.2023.08.027

IF: 6.124

2023-01-01

JACC Clinical Electrophysiology

Abstract:BACKGROUND In Brugada syndrome (BrS), phase 2 re-excitation/re-entry (P2R) induced by the transient outward potassium current (Ito) is a proposed arrhythmia mechanism; yet, the most common genetic defects are loss-of-function sodium channel mutations.OBJECTIVES The authors used computer simulations to investigate how sodium channel dysfunction affects P2Rmediated arrhythmogenesis in the presence and absence of Ito.METHODS Computer simulations were carried out in 1-dimensional cables and 2-dimensional tissue using guinea pig and human ventricular action potential models.RESULTS In the presence of Ito sufficient to generate robust P2R, reducing sodium current (INa) peak amplitude alone only slightly potentiated P2R. When INa inactivation kinetics were also altered to simulate reported effects of BrS mutations and sodium channel blockers, however, P2R occurred even in the absence of Ito. These effects could be potentiated by delaying L-type calcium channel activation or increasing ATP-sensitive potassium current, consistent with experimental and clinical findings. INa-mediated P2R also accounted for sex-related, day and night-related, and fever related differences in arrhythmia risk in BrS patients.CONCLUSIONS Altered INa kinetics synergize powerfully with reduced INa amplitude to promote P2R-induced arrhythmias in BrS in the absence of Ito, establishing a robust mechanistic link between altered INa kinetics and the P2R-mediated arrhythmia mechanism.(c) 2023 by the American College of Cardiology Foundation.
Catheter ablation as an adjunctive therapy to ICD implantation in Brugada Syndrome

Ioannis Doundoulakis,Sotirios Chiotis,Luigi Pannone,Domenico Giovanni Della Rocca,Antonio Sorgente,Athanasios Kordalis,Roberto Scacciavillani,Stefanos Zafeiropoulos,Lorenzo Marcon,Giampaolo Vetta,Eirini Pagkalidou,Gezim Bala,Alexandre Almorad,Erwin Ströker,Juan Sieira,Mark La Meir,Pedro Brugada,Dimitrios Tsiachris,Andrea Sarkozy,Gian Battista Chierchia,Carlo de Asmundis

DOI: https://doi.org/10.1093/ehjqcco/qcae040

2024-05-22

European Heart Journal - Quality of Care and Clinical Outcomes

Abstract:Abstract Background Brugada Syndrome (BrS) is a life-threatening cardiac arrhythmia disorder associated with an increased risk of ventricular arrhythmias (VAs) and sudden cardiac death. Current management primarily relies on implantable cardioverter-defibrillators (ICDs), but patients may experience ICD shocks. Catheter ablation (CA) has emerged as a potential intervention to target the arrhythmogenic substrate. This systematic review aims to evaluate the safety and efficacy of CA in BrS patients. Methods and results Studies with BrS patients undergoing CA for VAs were included. Fourteen studies that involved a total population of 709 BrS patients, with CA performed in 528 of them, were included. CA resulted in the non-inducibility of VAs in 91% (95% CI: 83–99, I2 = 76%) and resolution of type 1 ECG Brugada pattern in 88% (95% CI: 81–96.2, I2 = 91%) of the patients. After a mean follow-up of 30.7 months, 87% (95% CI: 80–94, I2 = 82%) of patients remained free from VAs. The incidence of VAs during follow-up was significantly lower in the ablation cohort in comparison to the group receiving only ICD therapy (OR = 0.03, 95% CI: 0.01–0.12, I2 = 0%). Conclusion CA shows potential as a therapeutic approach to reduce VAs and improve outcomes in BrS patients. While further research with a long follow-up period is required to confirm these findings, it represents a valuable tool as an add-on intervention to ICD implantation in BrS patients with a high burden of VAs.

cardiac & cardiovascular systems
Simulation of Brugada Syndrome Using Cellular and Three-Dimensional Whole-Heart Modeling Approaches

Ling Xia,Yu Zhang,Henggui Zhang,Qing Wei,Feng Liu,Stuart Crozier

DOI: https://doi.org/10.1088/0967-3334/27/11/006

2006-01-01

Physiological Measurement

Abstract:Brugada syndrome (BS) is a genetic disease identified by an abnormal electrocardiogram ( ECG) ( mainly abnormal ECGs associated with right bundle branch block and ST-elevation in right precordial leads). BS can lead to increased risk of sudden cardiac death. Experimental studies on human ventricular myocardium with BS have been limited due to difficulties in obtaining data. Thus, the use of computer simulation is an important alternative. Most previous BS simulations were based on animal heart cell models. However, due to species differences, the use of human heart cell models, especially a model with three-dimensional whole-heart anatomical structure, is needed. In this study, we developed a model of the human ventricular action potential (AP) based on refining the ten Tusscher et al (2004 Am. J. Physiol. Heart Circ. Physiol. 286 H1573 - 89) model to incorporate newly available experimental data of some major ionic currents of human ventricular myocytes. These modified channels include the L-type calcium current (ICaL), fast sodium current (I-Na), transient outward potassium current (I-to), rapidly and slowly delayed rectifier potassium currents (I-Kr and I-Ks) and inward rectifier potassium current (I-Ki). Transmural heterogeneity of APs for epicardial, endocardial and mid-myocardial (M) cells was simulated by varying the maximum conductance of IKs and Ito. The modified AP models were then used to simulate the effects of BS on cellular AP and body surface potentials using a three-dimensional dynamic heart - torso model. Our main findings are as follows. (1) BS has little effect on the AP of endocardial or mid-myocardial cells, but has a large impact on the AP of epicardial cells. (2) A likely region of BS with abnormal cell AP is near the right ventricular outflow track, and the resulting ST-segment elevation is located in the median precordium area. These simulation results are consistent with experimental findings reported in the literature. The model can reproduce a variety of electrophysiological behaviors and provides a good basis for understanding the genesis of abnormal ECG under the condition of BS disease.

Angina, exercise and food.

Brugada Syndrome: Clinical, Genetic, Molecular, Cellular, and Ionic Aspects

Patient-Specific and Genome-Edited Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Brugada Syndrome

Patient-specific Ipsc-Derived Cardiomyocytes Reveal Aberrant Activation of Wnt/β-catenin Signaling in SCN5A-related Brugada Syndrome

Cellular Modeling and Simulation of Brugada Syndrome

Activation of ENaC by AVP contributes to the urinary concentrating mechanism and dilution of plasma.

Ablation for the treatment of Brugada syndrome: current status and future prospects

Long-Term Outcomes of Brugada Substrate Ablation: A Report from BRAVO (brugada Ablation of VF Substrate Ongoing Multicenter Registry).

Novelties in Brugada Syndrome: Complex Genetics, Risk Stratification, and Catheter Ablation

Genetic and Molecular Mechanisms in Brugada Syndrome

Brugada syndrome: current clinical aspects and risk stratification

Why Is Only Type 1 Electrocardiogram Diagnostic of Brugada Syndrome? Mechanistic Insights From Computer Modeling

Brugada syndrome: identification of subjects at risk and therapy

Brugada Syndrome: From Molecular Mechanisms and Genetics to Risk Stratification

Efficacy and safety of catheter ablation for Brugada syndrome: an updated systematic review

Brugada Syndrome: Focus for the General Pediatrician

Characterization of the Epicardial Substrate for Catheter Ablation of Brugada Syndrome.

Incidence, recurrence and management of electrical storm in Brugada syndrome

Phase 2 Re-Entry Without Ito: Role of Sodium Channel Kinetics in Brugada Syndrome Arrhythmias.

Catheter ablation as an adjunctive therapy to ICD implantation in Brugada Syndrome

Simulation of Brugada Syndrome Using Cellular and Three-Dimensional Whole-Heart Modeling Approaches